mabvax therapeutics holdings, inc. (nasdaq: mbvx) … · mabvax therapeutics holdings, inc....
TRANSCRIPT
Value Proposition:• Three active Phase 1 trials for pancreatic, lung and gastric/colon cancers • Safety and targeting speci�city demonstrated in two Phase 1a clinical trials in 50 patients - Parental therapeutic antibody establishes pathway for targeted therapeutic approaches - Radioimmunotherapy agent Phase 1 data expected 2018 - ImmunoPET imaging diagnostic agent entering Phase 1b for pancreatic cancer patients for surgical resection • Robust research portfolio includes advanced Tn program for ovarian and triple negative breast cancer • CAR-T research program in collaboration with Memorial Sloan Kettering Cancer Center
• Strong intellectual property portfolio through 2036
MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs for the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer (PDAC) and other CA19-9 positive tumors. CA19-9 is expressed in over 90% of PDAC and in other diseases including small cell lung, colon and other GI cancers. CA19-9 plays a role in tumor adhesion and metastasis, and is a marker of an aggressive cancer phenotype. CA19-9 serum levels are considered a valuable adjunct in the diagnosis, prognosis and treatment monitoring of PDAC. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and demonstrated early safety, speci�city for the target and a potential e�cacy signal. Patient dosing has commenced for our lead development program in a Phase 1 clinical study of the Company's Radioimmunotherapy (RIT) product, MVT-1075.
Management
J. David Hansen President, CEO and Chairman Avanir Pharmaceuticals, Xenerex Biosciences, Dura Pharmaceuticals, Schering-Plough, Key, BMS
Philip O. Livingston, M.D. Chief Scienti�c O�cer Memorial Sloan Kettering Cancer Center
Gregory P. Hanson, CMA, MBAChief Financial O�cerAvanir Pharmaceuticals, Mast Therapeutics, Brinson Patrick Securities, Ford Motor Company
Wolfgang Scholz, Ph.D. VP, Antibody Discovery Avanir, Xenerex Biosciences, Tanabe Research Laboratories USA, Desmos, Scripps Research Institute
Paul W. Ma�uid, Ph.D.EVP, Research and Development AAI Pharma Services, Amylin, Arena, Biopharmalogics, Glaxo Research Institute
Paul F. Resnick, M.D. VP and Chief Business O�cerJuventas Therapeutics, Intellikine, P�zer, Rinat Neuroscience, Intermune, Roche
Board of Directors
J. David HansenPresident, CEO and Chairman
Kenneth M. Cohen Founder, Former President and CEO of Somaxon Pharmaceuticals, Synbiotics,
Je�rey F. Eisenberg Former CEO Noven Pharmaceuticals, Former Acting Gen Counsel IVAX
Philip O. Livingston, M.D. Corporate O�cer
Paul V. Maier Former CFO Sequenom Inc., Former Sr. VP & CFO Ligand Pharmaceuticals
Thomas C. Varvaro CFO of ChromaDex, Fast Heat, Leaf Bakery
Pipeline:
MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Road,Suite 400, San Diego, CA 92121 Tel: [email protected] www.mabvax.com
NASDAQ: MBVX
Price*: $.72
Market Cap*: $7.99M
Shares Outstanding: 11.1M
*As of September 13, 2017
Program Lead-Op Pre-IND Phase 1 Phase 2Discovery
HuMab-5B1 for Pancreatic Cancer and CA19-9 malignancies including Lung and GI Cancers
Therapeutic (MVT-5873): Monotherapy
Radioimmunotherapy (MVT-1075)
CAR-T-Sialyl Lewisa
Therapeutic (MVT-5873): + Chemo
HuMab-Tn
CAR-T-GD2
Tn for Breast and Ovarian Cancer
CAR-T Programs - Utilize MabVax’s Binding Domains
ImmunoPET Imaging (MVT-2163)
Metastatic Pancreatic and Lung Cancer therapeutic
Cold dose to support RIT and PET
First line Pancreatic Cancer therapeutic
Diagnostic for pre-surgical assessment
Ovarian & Triple Negative Breast Cancer
Pancreatic and GI
Neuro/ Endocrine
Investor Contact:Jenene Thomas
Jenene Thomas Communications Tel: 908-938-1475
Fully human antibody minimizes immunogenicity. Binding sequence re�ects the patient’s immune system response to the target antigen
Focused Discovery Screening Optimized Therapy
Lead Clinical Program - RIT (MVT-1075)MVT-1075 combines established enhanced e�cacy of radiation therapy with the HuMab-5B1 tumor targeting speci�city to potentially enhance the anti-cancer e�ects.
Proprietary Approach to the Discovery and Development of Novel Fully Human Antibody Therapy and Diagnostic Agents
Vaccinated Cancer PatientsIdentify Optimal Antibody
from Elite Responders
Antibody Based Therapeutic Agent to Treat Very Di�cult Cancers Such as Pancreatic, Small Cell Lung and Colon
Established Safety, PKand Responder Subset
Established safety, speci�city, accumulation on tumor, and
dose strategy for RIT
Immuno-PET Imaging (MVT-2163)
• Target signi�cantly over expressed on cancers • Antibody has high degree of speci�city for tumors
• Antibody readily accumulates on cancers
• Beta-emitting radionuclide with 6.7 day half-life
• Localized tumor cell killingRIT(MVT-1075)
Therapeutic Antibody (MVT-5873)
Lead Program: RIT (MVT-1075) Developemnt Milestones Expected to Drive Value
H12017
Q42017
Q12018
Q22018
Preclin @ AACR Interim Safety & E�cacy
AAPS Poster
• File Orphan Drug Designation
• Phase 1a Interim AACR or ASCO
✓
✓
Phase 1 FIH Dose✓
•